Get started Log in

COYA — Coya Therapeutics Share News

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Market Cap
$92.42m
Enterprise Value
$49.24m
Revenue
$7.95m

Brief: Coya Therapeutics Appoints Industry And Drug Development Veteran Dr Fred Grossman To President And Chief Medical Officer Succeeding Dr Adrian Hepner
05/07/2023 13:42
Brief: Coya Therapeutics Inc Says Expansion Of Its Patent Estate For COYA 301, Company's Low-Dose IL-2 (ld IL-2) Subcutaneous Administration Product Candidate
20/06/2023 12:13
U.S. RESEARCH ROUNDUP-Brown-Forman, Monster Beverage, Wynn Resorts
08/06/2023 08:14
U.S. STOCKS ON THE MOVE-Biogen, Phoenix Motor, Mastercard
07/06/2023 18:54
U.S. STOCKS ON THE MOVE-Energy sector, Affirm, Stitch Fix
07/06/2023 17:04
Coya rises on positive data from Alzheimer's disease treatment trial
07/06/2023 15:45
Brief: Coya Therapeutics Strengthens Scientific Advisory Board
05/06/2023 12:23
Brief: Coya Therapeutics Inc Says On May 22, Chardan Capital Markets Agreed To End Restricted Period With Respect To Certain Shares Subject To Lock-Up Agreements
23/05/2023 22:48
Coya rises on data from Alzheimer's disease treatment trial
16/05/2023 17:29
Brief: Coya Therapeutics’ Coya 301 Halted Cognitive Decline In Open Label Study In Patients With Alzheimer’S
16/05/2023 12:05
Brief: Coya Therapeutics Inc Provides Business Update And Reports Q1 2023 Unaudited Financial Results
10/05/2023 13:55
Brief: Coya Therapeutics To Present Biomarker And Preliminary Efficacy Clinical Data For Coya 301 For The Treatment Of Patients With Alzheimer’S Disease (Ad) At The 2023 Keystone Symposia Meeting For Neurodegeneration Held On May 15-19Th, 2023
31/03/2023 12:09
Brief: Coya Therapeutics, Inc. Provides Business Update And Reports FY 2022 Unaudited Financial Results
29/03/2023 21:34
U.S. STOCKS ON THE MOVE-CVRx, Tesla, So-Young International
21/03/2023 18:25
U.S. STOCKS ON THE MOVE-Knight-Swift, BioNTech, US regional banks
21/03/2023 16:01
Coya Therapeutics gains on positive ALS therapy data
21/03/2023 14:08
Brief: Coya Therapeutics Inc Announces Positive Results From A Proof-Of-Concept Academic Clinical Study For Coya 302 In Amyotrophic Lateral Sclerosis (Als)
21/03/2023 11:31
Brief: Coya Therapeutics Announces Agreement With Dr. Reddy's Laboratories To License Its Proposed Biosimilar Abatacept For Development And Commercialization Of Coya 302 For Treatment Of Neurodegenerative Diseases
20/03/2023 11:08
Brief: Coya Therapeutics To Present ALS Clinical Study Data At 2023 MDA Conference
27/02/2023 12:11
Brief: Coya Therapeutics, Inc. Announces Expansion Of Exclusive Worldwide Licensing Agreement With Arscience Biotherapeutics, Inc. For Development And Commercialization Of Coya 301, Coya’S Low-Dose Interleukin 2 (Il-2) Product Candidate
15/02/2023 13:17